Emergex Announces Positive Phase I Trial Data for DengueTcP™, Its Novel T Cell-Priming Immune Set-Point Candidate
No treatment-related serious adverse events were reported, and the majority of adverse events were mild and transient.
- No treatment-related serious adverse events were reported, and the majority of adverse events were mild and transient.
- From a safety perspective, both doses were considered acceptable for use in further trials.
- These data demonstrate that our product platform has an acceptable safety profile and successfully mobilises viral-specific CD8+ T cells, which may elicit broad and long-term immune memory.
- Follow-up of trial participants took place over a six-month period following first injection.